DAIICHI SANKYO, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $79B
- Website
- http://daiichisankyo.us
Prasugrel/Clopidogrel Maintenance Dose Washout Study
- First Posted Date
- 2009-11-17
- Last Posted Date
- 2021-06-28
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 56
- Registration Number
- NCT01014624
- Locations
- 🇺🇸
Scripps Clinic, La Jolla, California, United States
🇺🇸Black Hills Clinical Research Center, Rapid City, South Dakota, United States
🇺🇸University of Florida Health Science Center Shands Jacksonville, Jacksonville, Florida, United States
Safety Study of PLX108-01 in Patients With Solid Tumors
- First Posted Date
- 2009-10-30
- Last Posted Date
- 2022-01-04
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 132
- Registration Number
- NCT01004861
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Evergreen Hematology & Oncology, Spokane, Washington, United States
🇺🇸Rocky Mountain Cancer Centers, Denver, Colorado, United States
CS-1008 With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2009-10-08
- Last Posted Date
- 2012-09-10
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 109
- Registration Number
- NCT00991796
- Locations
- 🇩🇪
Asklepios Fachkliniken Munchen Gauting, Gauting, Germany
🇩🇪Zentrum fur Pneumologie und Thoraxchirurgie, Grobhansdorf, Germany
Efficacy Study for AC220 to Treat Acute Myeloid Leukemia (AML)
- First Posted Date
- 2009-10-05
- Last Posted Date
- 2019-12-11
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 333
- Registration Number
- NCT00989261
- Locations
- 🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada
🇺🇸Northwestern Memorial Hospital, Chicago, Illinois, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy
- First Posted Date
- 2009-09-30
- Last Posted Date
- 2020-11-05
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 84
- Registration Number
- NCT00986440
- Locations
- 🇮🇹
Institute for Cancer Research and Treatment - IRCC, Candiolo, Torino, Italy
🇵🇱Wojewodzki Szpital Specjalistyczny, Bytom, Poland
🇵🇱NZOZ ONKOLOG s.c., Warszawa, Poland
Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).
- First Posted Date
- 2009-09-29
- Last Posted Date
- 2019-03-05
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 8292
- Registration Number
- NCT00986154
- Locations
- 🇧🇪
Investigational Site 1602, Lier, Belgium
🇦🇹Investigational Site 2803, Graz, Austria
🇦🇹Investigational Site 2800, Innsbruck, Austria
CS-1008 Used With Irinotecan Versus Irinotecan Alone in Subjects With Metastatic Colorectal Carcinoma Who Failed First-line Treatment With Oxaliplatin
- First Posted Date
- 2009-08-31
- Last Posted Date
- 2012-01-31
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 8
- Registration Number
- NCT00969033
- Locations
- 🇬🇧
Royal Marsden Hospital, Sutton, Surrey, United Kingdom
🇬🇧Clatterbridge Hospital, Bebington, Wirral, United Kingdom
🇬🇧Nottingham City Hospital, Nottingham, Notts, United Kingdom
Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy
- Conditions
- Interventions
- First Posted Date
- 2009-08-28
- Last Posted Date
- 2020-05-04
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 100
- Registration Number
- NCT00967616
- Locations
- 🇨🇱
Fundacion Arturo Lopez Perez, Santiago, Chile
🇺🇸Victor Priego, Bethesda, Maryland, United States
🇺🇸St. Jude Heritage Medical Group, Fullerton, California, United States
Olmesartan Comparison to Losartan in Hypertensive Subjects
- Conditions
- Interventions
- First Posted Date
- 2009-07-30
- Last Posted Date
- 2011-03-09
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 941
- Registration Number
- NCT00949884
Combination Chemotherapy With CS-1008 to Treat Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-07-24
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 24
- Registration Number
- NCT00945191
- Locations
- 🇺🇸
University of Oklahoma, Oklahoma City, Oklahoma, United States
🇺🇸Barnes Jewish Hospital, Saint Louis, Missouri, United States
🇺🇸Univ. Alabama, Birmingham, Alabama, United States